CA2494372C - Anticorps se fixant de facon immunospecifique a des recepteurs trail - Google Patents

Anticorps se fixant de facon immunospecifique a des recepteurs trail Download PDF

Info

Publication number
CA2494372C
CA2494372C CA2494372A CA2494372A CA2494372C CA 2494372 C CA2494372 C CA 2494372C CA 2494372 A CA2494372 A CA 2494372A CA 2494372 A CA2494372 A CA 2494372A CA 2494372 C CA2494372 C CA 2494372C
Authority
CA
Canada
Prior art keywords
replaced
polypeptide
antibody
antibodies
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2494372A
Other languages
English (en)
Other versions
CA2494372A1 (fr
Inventor
Theodora Salcedo
Steven M. Ruben
Craig A. Rosen
Vivian R. Albert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of CA2494372A1 publication Critical patent/CA2494372A1/fr
Application granted granted Critical
Publication of CA2494372C publication Critical patent/CA2494372C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des anticorps et des molécules apparentées se fixant de façon immunospécifique au récepteur TRAIL, TR4. Ces anticorps peuvent être, par exemple, mis en application pour la prévention et le traitement de cancers ou d'autres maladies prolifératives. Elle concerne également des molécules d'acides nucléiques codant des anticorps anti-TR4, des vecteurs et des cellules hôtes contenant ces acides nucléiques et des méthodes servant à les produire. Elle concerne également des méthodes et des compositions servant à prévenir, détecter, diagnostiquer, traiter ou améliorer un trouble ou une maladie, en particulier, le cancer ou d'autres maladies hyperprolifératives, ce qui consiste à administrer à un animal, de préférence un humain, une quantité efficace d'un ou plusieurs anticorps ou fragments ou variantes de ces anticorps, ou des molécules apparentées, se fixant de manière immunospécifique au récepteur TRAIL, TR4.
CA2494372A 2002-08-15 2003-08-15 Anticorps se fixant de facon immunospecifique a des recepteurs trail Expired - Lifetime CA2494372C (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US40338202P 2002-08-15 2002-08-15
US60/403,382 2002-08-15
US42573002P 2002-11-13 2002-11-13
US60/425,730 2002-11-13
US46805003P 2003-05-06 2003-05-06
US60/468,050 2003-05-06
PCT/US2003/025457 WO2004016753A2 (fr) 2002-08-15 2003-08-15 Anticorps se fixant de facon immunospecifique a des recepteurs trail

Publications (2)

Publication Number Publication Date
CA2494372A1 CA2494372A1 (fr) 2004-02-26
CA2494372C true CA2494372C (fr) 2013-05-28

Family

ID=31892094

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2494372A Expired - Lifetime CA2494372C (fr) 2002-08-15 2003-08-15 Anticorps se fixant de facon immunospecifique a des recepteurs trail

Country Status (4)

Country Link
EP (1) EP1534336A4 (fr)
AU (1) AU2003259835A1 (fr)
CA (1) CA2494372C (fr)
WO (1) WO2004016753A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8288439B2 (en) * 2003-11-04 2012-10-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for the inhibition of HIV-1 replication
CN101031319A (zh) * 2003-12-11 2007-09-05 舍林股份公司 改善放射性标记药物的功效的放射增敏剂缀合物
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
PE20090499A1 (es) 2007-08-09 2009-05-18 Boehringer Ingelheim Int Anticuerpos anti-cd37
KR20110009095A (ko) 2008-03-03 2011-01-27 더 유니버시티 오브 마이애미 동종 이계 암 세포-기반 면역 요법
JP2015517511A (ja) * 2012-05-16 2015-06-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｄ３７抗体とｉｃｅ（イフォスファミド、カルボプラチン、エトポシド）の併用
ES2812208T3 (es) 2013-03-14 2021-03-16 Bristol Myers Squibb Co Combinación de un agonista de DR5 y un antagonista de anti-PD-1 y métodos de uso
US20180028521A1 (en) 2016-07-29 2018-02-01 Janssen Pharmaceutica Nv Methods of Treating Prostate Cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002500877A (ja) * 1998-01-26 2002-01-15 ジェネンテク・インコーポレイテッド 細胞死レセプター４（ｄｒ４）に対する抗体及びその使用
DK1303293T3 (da) * 2000-07-27 2009-03-30 Genentech Inc Sekventiel indgivelse af CPT-11 og APO-2L-polypeptid
NZ529359A (en) * 2001-05-25 2007-04-27 Human Genome Sciences Inc Antibodies that immunospecifically bind to a TR4 polypeptide or polypeptide fragment or variant of TR4 and their use in a medicament for treating cancer

Also Published As

Publication number Publication date
EP1534336A2 (fr) 2005-06-01
WO2004016753A2 (fr) 2004-02-26
WO2004016753A3 (fr) 2004-06-17
EP1534336A4 (fr) 2005-12-14
AU2003259835A8 (en) 2004-03-03
CA2494372A1 (fr) 2004-02-26
AU2003259835A1 (en) 2004-03-03

Similar Documents

Publication Publication Date Title
US7348003B2 (en) Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
KR100942393B1 (ko) Ｔｒａｉｌ 수용체에 면역특이적으로 결합하는 항체
US20050214205A1 (en) Antibodies that immunospecifically bind to TRAIL receptors
US20050214208A1 (en) Antibodies that immunospecifically bind to TRAIL receptors
US20050214207A1 (en) Antibodies that immunospecifically bind toTRAIL receptors
US20050214209A1 (en) Antibodies that immunospecifically bind to TRAIL receptors
US20050129616A1 (en) Antibodies that immunospecifically bind to TRAIL receptors
US20060269555A1 (en) Antibodies that immunospecifically bind to TRAIL receptors
US20050214210A1 (en) Antibodies that immunospecifically bind to TRAIL receptors
US20090226429A1 (en) Antibodies That Immunospecifically Bind to TRAIL Receptors
US20060062786A1 (en) Antibodies that immunospecifically bind to TRAIL receptors
US20070292411A1 (en) Antibodies That Immunospecifically Bind to TRAIL Receptors
US20030228309A1 (en) Antibodies that immunospecifically bind to TRAIL receptors
AU2002309647A1 (en) Antibodies that immunospecifically bind to trail receptors
CA2524737A1 (fr) Anticorps se liant de maniere immunospecifique aux recepteurs trail
CA2494372C (fr) Anticorps se fixant de facon immunospecifique a des recepteurs trail
US20050214206A1 (en) Antibodies that immunospecifically bind to TRAIL receptors
WO2003042367A2 (fr) Anticorps se liant specifiquement au niveau immunitaire a des recepteurs trail
EP1339426A2 (fr) Anticorps a liaison immunospecifique avec les recepteurs "trail"
AU2008201237A1 (en) Antibodies that Immunospecifically Bind to Trail Receptors
MXPA04006042A (es) Anticuerpos que se unen inmunoespecificamente a receptores de trail.

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20230815